Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2005 1
2006 2
2007 4
2009 2
2010 1
2014 1
2015 4
2016 2
2017 1
2018 4
2019 7
2020 5
2021 2
2022 3
2023 3
2024 5
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Cardiac MRI study of adverse events in patients treated with immune checkpoint inhibitors: a prospective cohort study of cardiac adverse events.
Losurdo A, Panico C, Catalano C, Serio S, Giordano L, Monti L, Catapano F, Figliozzi S, D'Andrea C, Dipasquale A, Persico P, Di Muzio A, Cremonesi M, Marchese A, Tronconi MC, Perrino M, Finocchiaro G, Lugli E, Francone M, Santoro A, Condorelli G, Simonelli M, Kallikourdis M. Losurdo A, et al. Among authors: finocchiaro g. J Immunother Cancer. 2025 Mar 18;13(3):e010568. doi: 10.1136/jitc-2024-010568. J Immunother Cancer. 2025. PMID: 40107671 Free PMC article.
RORγ Bridges Cancer-Driven Lipid Dysmetabolism and Myeloid Immunosuppression.
Bleve A, Incerti M, Consonni FM, Garlatti V, Ballerini G, Pandolfo C, Monari MN, Serio S, Pistillo D, Sironi M, Alì C, Manfredi M, Barberis E, Finocchiaro G, Cassatella MA, Panico C, Condorelli G, Sica A. Bleve A, et al. Among authors: finocchiaro g. Cancer Discov. 2025 Jul 3;15(7):1505-1525. doi: 10.1158/2159-8290.CD-24-0199. Cancer Discov. 2025. PMID: 40066819 Free PMC article.
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.
Wu YL, Guarneri V, Voon PJ, Lim BK, Yang JJ, Wislez M, Huang C, Liam CK, Mazieres J, Tho LM, Hayashi H, Nhung NV, Chia PL, de Marinis F, Raskin J, Zhou Q, Finocchiaro G, Le AT, Wang J, Dooms C, Kato T, Nadal E, Hin HS, Smit EF, Wermke M, Tan D, Morise M, O'Brate A, Adrian S, Pfeiffer BM, Stroh C, Juraeva D, Strotmann R, Goteti K, Berghoff K, Ellers-Lenz B, Karachaliou N, Le X, Kim TM; INSIGHT 2 investigators. Wu YL, et al. Among authors: finocchiaro g. Lancet Oncol. 2024 Aug;25(8):989-1002. doi: 10.1016/S1470-2045(24)00270-5. Lancet Oncol. 2024. PMID: 39089305 Clinical Trial.
Management of patients with extensive small-cell lung cancer in the immunotherapy era: An Italian consensus through a Delphi approach.
Ceresoli GL, Rossi G, Agustoni F, Bonomi L, Borghetti P, Bulotta A, Casartelli C, Cerea G, Colonese F, Del Signore E, Finocchiaro G, Gianoncelli L, Grisanti S, Maiolani M, Pagni F, Proto C, Rijavec E, Vittimberga I, Arcangeli S, Filippi AR. Ceresoli GL, et al. Among authors: finocchiaro g. Crit Rev Oncol Hematol. 2024 Jul;199:104247. doi: 10.1016/j.critrevonc.2023.104247. Epub 2024 Feb 1. Crit Rev Oncol Hematol. 2024. PMID: 38307393 Review.
The Smokers Health Multiple ACtions (SMAC-1) Trial: Study Design and Results of the Baseline Round.
Antonicelli A, Muriana P, Favaro G, Mangiameli G, Lanza E, Profili M, Bianchi F, Fina E, Ferrante G, Ghislandi S, Pistillo D, Finocchiaro G, Condorelli G, Lembo R, Novellis P, Dieci E, De Santis S, Veronesi G. Antonicelli A, et al. Among authors: finocchiaro g. Cancers (Basel). 2024 Jan 18;16(2):417. doi: 10.3390/cancers16020417. Cancers (Basel). 2024. PMID: 38254906 Free PMC article.
The Era of Immunotherapy in Small-Cell Lung Cancer: More Shadows Than Light?
Rossi S, Pagliaro A, Michelini A, Navarria P, Clerici E, Franceschini D, Toschi L, Finocchiaro G, Scorsetti M, Santoro A. Rossi S, et al. Among authors: finocchiaro g. Cancers (Basel). 2023 Dec 8;15(24):5761. doi: 10.3390/cancers15245761. Cancers (Basel). 2023. PMID: 38136306 Free PMC article. Review.
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results.
Gutierrez M, Lam WS, Hellmann MD, Gubens MA, Aggarwal C, Tan DSW, Felip E, Chiu JWY, Lee JS, Yang JC, Garon EB, Finocchiaro G, Ahn MJ, Luft A, Landers GA, Basso A, Ma H, Kobie J, Palcza J, Cristescu R, Fong L, Snyder A, Yuan J, Herbst RS. Gutierrez M, et al. Among authors: finocchiaro g. Nat Med. 2023 Jul;29(7):1718-1727. doi: 10.1038/s41591-023-02385-6. Epub 2023 Jul 10. Nat Med. 2023. PMID: 37429923 Clinical Trial.
45 results